Siliq
These highlights do not include all the information needed to use SILIQ safely and effectively. See full prescribing information for SILIQ. SILIQ (brodalumab) injection, for subcutaneous use Initial U.S. Approval: 2017
Approved
Approval ID
1a550c33-456a-4833-814e-8591aea7c688
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Sep 1, 2023
Manufacturers
FDA
Bausch Health US LLC
DUNS: 831922468
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Brodalumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code0187-0004
Application NumberBLA761032
Product Classification
M
Marketing Category
C73585
G
Generic Name
Brodalumab
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateSeptember 1, 2023
FDA Product Classification
INGREDIENTS (1)
BRODALUMABActive
Quantity: 210 mg in 1 1
Code: 6ZA31Y954Z
Classification: ACTIB